PMID- 29567019
OWN - NLM
STAT- MEDLINE
DCOM- 20181018
LR  - 20181018
IS  - 1773-0597 (Electronic)
IS  - 0181-5512 (Linking)
VI  - 41
IP  - 3
DP  - 2018 Mar
TI  - [Systemic safety following intravitreal injections of anti-VEGF].
PG  - 271-276
LID - S0181-5512(18)30086-X [pii]
LID - 10.1016/j.jfo.2017.11.006 [doi]
AB  - The goal of this manuscript is to assess data suggesting that intravitreal 
      injection of anti-vascular endothelial growth factors (anti-VEGFs) could result 
      in systemic adverse events (AEs). The class-specific systemic AEs should be 
      similar to those encountered in cancer trials. The most frequent AE observed in 
      oncology, hypertension and proteinuria, should thus be the most common expected 
      in ophthalmology, but their severity should be lower because of the much lower 
      doses of anti-VEGFs administered intravitreally. Such AEs have not been 
      frequently reported in ophthalmology trials. In addition, pharmacokinetic and 
      pharmacodynamic data describing systemic diffusion of anti-VEGFs should be 
      interpreted with caution because of significant inconsistencies reported. Thus, 
      safety data reported in ophthalmology trials and pharmacokinetic/pharmacodynamic 
      data provide robust evidence that systemic events after intravitreal injection 
      are very unlikely. Additional studies are needed to explore this issue further, 
      as much remains to be understood about local and systemic side effects of 
      anti-VEGFs.
CI  - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.
FAU - Baillif, S
AU  - Baillif S
AD  - Departement d'ophtalmologie, hopital Pasteur, 30, voie Romaine, 06000 Nice cedex 
      1, France. Electronic address: baillif.s@chu-nice.fr.
FAU - Levy, B
AU  - Levy B
AD  - Institut des vaisseaux et du sang, departement physiologie clinique, Inserm U970, 
      hopital Lariboisiere, 75010 Paris, France.
FAU - Girmens, J-F
AU  - Girmens JF
AD  - Departement d'ophtalmologie du Professeur-Sahel-&-CIC, hopital Quinze-Vingt, 
      75012 Paris, France.
FAU - Dumas, S
AU  - Dumas S
AD  - Clinique Nord-Vision, 59800 Lille, France.
FAU - Tadayoni, R
AU  - Tadayoni R
AD  - Departement d'ophtalmologie, hopitaux de Paris, hopital Lariboisiere, 75010 
      Paris, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Tolerance systemique des injections intravitreennes d'anti-VEGF.
DEP - 20180319
PL  - France
TA  - J Fr Ophtalmol
JT  - Journal francais d'ophtalmologie
JID - 7804128
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 15C2VL427D (aflibercept)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/administration & dosage/*adverse 
      effects/pharmacokinetics/therapeutic use
MH  - Antineoplastic Agents/adverse effects
MH  - Bevacizumab/administration & dosage/adverse effects/pharmacokinetics
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Intravitreal Injections/adverse effects
MH  - Neoplasms/drug therapy
MH  - Patient Safety
MH  - Proteinuria/chemically induced
MH  - Ranibizumab/administration & dosage/adverse effects/pharmacokinetics
MH  - Receptors, Vascular Endothelial Growth Factor/administration & dosage
MH  - Recombinant Fusion Proteins/administration & dosage/adverse 
      effects/pharmacokinetics
MH  - Thromboembolism/chemically induced
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
MH  - Wound Healing/drug effects
OTO - NOTNLM
OT  - Aflibercept
OT  - Bevacizumab
OT  - Bevacizumab
OT  - Injections intravitreennes
OT  - Intravitreal injections
OT  - Pharmacocinetique
OT  - Pharmacodynamics
OT  - Pharmacodynamique
OT  - Pharmacokinetics
OT  - Ranibizumab
OT  - Tolerability
OT  - Tolerance
EDAT- 2018/03/24 06:00
MHDA- 2018/10/20 06:00
CRDT- 2018/03/24 06:00
PHST- 2017/06/26 00:00 [received]
PHST- 2017/10/22 00:00 [revised]
PHST- 2017/11/09 00:00 [accepted]
PHST- 2018/03/24 06:00 [pubmed]
PHST- 2018/10/20 06:00 [medline]
PHST- 2018/03/24 06:00 [entrez]
AID - S0181-5512(18)30086-X [pii]
AID - 10.1016/j.jfo.2017.11.006 [doi]
PST - ppublish
SO  - J Fr Ophtalmol. 2018 Mar;41(3):271-276. doi: 10.1016/j.jfo.2017.11.006. Epub 2018 
      Mar 19.